Helixmith Co., Ltd.
https://www.helixmith.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Helixmith Co., Ltd.
The Race Is On. When Will Korea Have Its Own Approved Gene Therapy?
Scrip takes a look at the landscape of the South Korean gene and cell therapy sector, which is under the spotlight with the implementation of a new cutting-edge biologics law.
Helixmith’s Plasmid DNA Therapeutic Moves Forward With New Formulation
South Korea's Helixmith reaches a milestone with a US FDA nod to use a new in-house developed formulation for its plasmid DNA therapeutic Engensis, said to be more suited to mass production, in its upcoming Phase III trials for diabetic peripheral neuropathy.
Paying For Gene Therapy: Biggest Cost Challenges Two To Three Years Away?
Only about one-quarter of the 40 gene therapies projected to launch by the end of 2025 would have potential US patient populations of more than 50,000. But a handful of treatments could target millions of individuals.
Paying For Gene Therapy: Biggest Cost Challenges Two To Three Years Away?
Only about one-quarter of the 40 gene therapies projected to launch by the end of 2025 would have potential US patient populations of more than 50,000. But a handful of treatments could target millions of individuals.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Nutraceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
- Other Names / Subsidiaries
-
- Cartexell
- Genebiotech Co., Ltd
- Neuromyon
- ViroMed Co., Ltd.
- VM BioPharma
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice